Teva's flagship drugs delivered a positive quarter and improved revenue forecast

Teva reported third-quarter results with revenues of $4.4 billion and Non-GAAP earnings of 86 cents per share, above analyst expectations. The company raised its annual revenue forecast to $16.7-17 billion. The stock rose about 1.5% in early trading.

Teva Pharmaceutical Industries reported its third-quarter 2026 results, with revenues of $4.4 billion and Non-GAAP earnings of 86 cents per share, exceeding analyst expectations of $4.23 billion in revenue and 72 cents per share. GAAP net income stood at $223 million. The company raised its annual revenue forecast to $16.7-17 billion, up from a previous forecast of $16.5-16.85 billion. Revenues from key original products grew by 33%, supporting the results. The stock rose about 1.5% in early trading on Wall Street. Additionally, Teva signed a commercialization agreement with Samsung Bioepis for two biosimilar drugs approved by the FDA. CEO Richard Francis noted that the performance reflects the implementation of the growth strategy and the company's financial resilience.